__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
KESIMPTA may be an appropriate choice for a range of patients and their lifestyles. These resources are designed to examine a number of patient types to help you in your treatment decision-making.
KESIMPTA can be a suitable option for patients at different stages of their RRMS journey
Patient descriptions are based on hypothetical patients representative of someone with active RRMS.
Patient identification videos
In this series of short videos, Dr Wallace Brownlee, Consultant Neurologist and Clinical Lead for the multiple sclerosis service at the National Hospital for Neurology and Neurosurgery, explores patient case studies and discusses treatment choices.
38-year-old female with poor prognostic markers
In this video, Dr Brownlee discusses the diagnostic investigations of a patient who presented with right optic neuritis with incomplete recovery and no previous history of neurological symptoms.
18-year-old female student with MRI activity
This video looks at the case of a young woman transitioning to adult care with a delayed diagnosis of MS and discusses how and when to escalate treatment in patients with MRI activity.
Prescribing information for KESIMPTA®▼ (ofatumumab) and adverse event reporting details can be found here.
Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1,2
*Women of childbearing potential should use effective contraception (methods that result in less than 1% pregnancy rates) while receiving KESIMPTA and for 6 months after the last administration of KESIMPTA.1,2
DMT, disease-modifying therapy; EDSS, expanded disability status scale; Gd+, gadolinium positive; MRI, magnetic resonance imaging; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.
References
- KESIMPTA Summary of Product Characteristics. Great Britain: Novartis Pharmaceuticals UK Ltd; August 2023.
- KESIMPTA Summary of Product Characteristics. Novartis Ireland Limited; March 2023.
